A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Trial Profile

A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Mitoxantrone
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 02 Apr 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 05 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Oct 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top